{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:33:34Z","timestamp":1788456814171,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"23-24","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bmcl.2018.10.043","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T03:12:45Z","timestamp":1540523565000},"page":"3617-3621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads"],"prefix":"10.1016","volume":"28","author":[{"given":"Amit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kinneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebele","family":"Ezeadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herren","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changshou","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-1646","authenticated-orcid":false,"given":"Nazzareno","family":"Dimasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bmcl.2018.10.043_b0005","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2018.10.043_b0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"22","key":"10.1016\/j.bmcl.2018.10.043_b0015","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bmcl.2018.10.043_b0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bmcl.2018.10.043_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/mabs.27436","article-title":"Antibody-drug conjugates: present and future","volume":"6","author":"Beck","year":"2014","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.bmcl.2018.10.043_b0030","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.bmcl.2018.10.043_b0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1021\/bc5004982","article-title":"Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development","volume":"26","author":"Agarwal","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2018.10.043_b0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4161\/mabs.26632","article-title":"Methods for site-specific drug conjugation to antibodies","volume":"6","author":"Behrens","year":"2014","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.bmcl.2018.10.043_b0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"issue":"20","key":"10.1016\/j.bmcl.2018.10.043_b0050","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.biomaterials.2009.02.040","article-title":"Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers","volume":"30","author":"Lammers","year":"2009","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.bmcl.2018.10.043_b0055","first-page":"90","article-title":"Chemotherapy and immunotherapy combination in advanced prostate cancer","volume":"10","author":"Slovin","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"10.1016\/j.bmcl.2018.10.043_b0060","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.1549","article-title":"Synergistic drug combinations tend to improve therapeutically relevant selectivity","volume":"27","author":"Lehar","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"28","key":"10.1016\/j.bmcl.2018.10.043_b0065","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30(+) peripheral T-Cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bmcl.2018.10.043_b0070","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bmcl.2018.10.043_b0075","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-14-2993","article-title":"PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance","volume":"21","author":"Stern","year":"2015","journal-title":"Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.bmcl.2018.10.043_b0080","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab\u2013maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"40","key":"10.1016\/j.bmcl.2018.10.043_b0085","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1039\/C6OB01751G","article-title":"One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates","volume":"14","author":"Tang","year":"2016","journal-title":"Org Biomol Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2018.10.043_b0090","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/acs.bioconjchem.5b00244","article-title":"Site-specific dual antibody conjugation via engineered cysteine and selenocysteine residues","volume":"26","author":"Li","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2018.10.043_b0095","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1038\/s41598-017-08151-2","article-title":"Real-time analysis on drug-antibody ratio of antibody-drug conjugates for synthesis, process optimization, and quality control","volume":"7","author":"Tang","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.bmcl.2018.10.043_b0100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/anie.201608292","article-title":"Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates","volume":"56","author":"Levengood","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"issue":"40","key":"10.1016\/j.bmcl.2018.10.043_b0105","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.1002\/anie.201405702","article-title":"Cysteine-selective reactions for antibody conjugation","volume":"53","author":"Cal","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"10.1016\/j.bmcl.2018.10.043_b0110","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/bc500357n","article-title":"Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy","volume":"25","author":"Tumey","year":"2014","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2018.10.043_b0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"Pt B","key":"10.1016\/j.bmcl.2018.10.043_b0120","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jconrel.2015.09.032","article-title":"Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides","volume":"220","author":"Christie","year":"2015","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.bmcl.2018.10.043_b0125","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1021\/acs.bioconjchem.5b00355","article-title":"Hydrolytically stable site-specific conjugation at the n-terminus of an engineered antibody","volume":"26","author":"Thompson","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2018.10.043_b0130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","article-title":"Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.bmcl.2018.10.043_b0135","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/acs.molpharmaceut.6b00995","article-title":"efficient preparation of site-specific antibody-drug conjugates using cysteine insertion","volume":"14","author":"Dimasi","year":"2017","journal-title":"Mol Pharm"},{"issue":"15","key":"10.1016\/j.bmcl.2018.10.043_b0140","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1021\/acs.chemrev.7b00090","article-title":"Oximes and hydrazones in bioconjugation: mechanism and catalysis","volume":"117","author":"K\u00f6lmel","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2018.10.043_b0145","doi-asserted-by":"crossref","unstructured":"Mahmoodi MM, et al., Application of meta- and para-phenylenediamine as enhanced oxime ligation catalysts for protein labeling, PEGylation, immobilization and release. In: John E. Coligan et al., Current protocols in protein science\/editorial board, 2015. 79. pp. 15.4.1\u201315.4.28.","DOI":"10.1002\/0471140864.ps1504s79"},{"issue":"9","key":"10.1016\/j.bmcl.2018.10.043_b0150","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/1535-7163.MCT-11-0191","article-title":"In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen","volume":"10","author":"Wang","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.bmcl.2018.10.043_b0155","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/1535-7163.MCT-17-0982","article-title":"Antitumor activity of MEDI3726 (ADCT-401), a pyrrolobenzodiazepine antibody-drug conjugate targeting psma, in preclinical models of prostate cancer","volume":"17","author":"Cho","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.bmcl.2018.10.043_b0160","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bmcl.2018.10.043_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191046","article-title":"A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo","volume":"13","author":"Gallery","year":"2018","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.bmcl.2018.10.043_b0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjc.6603853","article-title":"Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells","volume":"97","author":"Pepper","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmcl.2018.10.043_b0175","article-title":"Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates","author":"Burke","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"44","key":"10.1016\/j.bmcl.2018.10.043_b0180","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1073\/pnas.1316026110","article-title":"Bispecific small molecule\u2013antibody conjugate targeting prostate cancer","volume":"110","author":"Kim","year":"2013","journal-title":"Proc Natl Acad Sci"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X1830845X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X1830845X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:28:37Z","timestamp":1760772517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X1830845X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":36,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0960894X1830845X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.10.043","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}